trial
as of 2026-07-01Study Evaluating The Effects Of Single Oral Doses Of NSA-789 On Auditory P50 Suppression In Schizophrenic Patients
NCTId NCT00781794
at a glance
Phase 1 · Withdrawn
Enrollment 0 (actual)
Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer
Primary completion 2009-08
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 1
Status
Withdrawn
Enrollment
0 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Triple
Start
2009-01
Primary completion
2009-08
Eligibility
ALL · 18 Years · 55 Years
Interventions & indications
Indications
Sponsors
Wyeth is now a wholly owned subsidiary of PfizerLead Sponsor
Sites
0 total
Facts & assertions
4 sourced
Enrollment
0
Phase
PHASE1
Primary Completion Date
2009-08
Status
WITHDRAWN
relationships
The graph out of here
drug
lead_sponsor
indication
indication
indication